Austar Lifesciences (AULS.F) Stock Overview
An investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AULS.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Austar Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.02 |
| 52 Week High | HK$0.02 |
| 52 Week Low | HK$0.02 |
| Beta | 0.89 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| AULS.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | -3.7% | -1.4% |
| 1Y | n/a | 10.2% | 16.4% |
Return vs Industry: Insufficient data to determine how AULS.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how AULS.F performed against the US Market.
Price Volatility
| AULS.F volatility | |
|---|---|
| AULS.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AULS.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AULS.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 1,468 | Mars Ho | www.austar.com.hk |
Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through Integrated Process and Packaging Equipment & Systems (IPS); Consulting, Digitalization and Construction (CDC); and Life Science Equipment and Consumables (SIC) segments. The company also offers clean utility equipment and chemical pharmaceutical preparation systems; bioprocess equipment and systems; clean room, automation control, and monitoring systems; powder and solid equipment and systems; aseptic freeze-drying, filling, and visual inspection solutions; pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; and laboratory one-stop solutions.
Austar Lifesciences Limited Fundamentals Summary
| AULS.F fundamental statistics | |
|---|---|
| Market cap | US$45.76m |
| Earnings (TTM) | US$4.99m |
| Revenue (TTM) | US$226.02m |
Is AULS.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AULS.F income statement (TTM) | |
|---|---|
| Revenue | CN¥1.53b |
| Cost of Revenue | CN¥1.24b |
| Gross Profit | CN¥293.27m |
| Other Expenses | CN¥259.47m |
| Earnings | CN¥33.81m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.066 |
| Gross Margin | 19.16% |
| Net Profit Margin | 2.21% |
| Debt/Equity Ratio | 39.0% |
How did AULS.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 20:14 |
| End of Day Share Price | 2026/06/29 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Austar Lifesciences Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Forrest Chan | CCB International Securities Limited |
| Tsz Man Chan | KGI Securities Co. Ltd. |